NCT03275701 (STRUCTR) is a NA clinical trial of Triumeq in Infection, Human Immunodeficiency Virus, sponsored by Mills Clinical Research.

Who is sponsoring NCT03275701?

NCT03275701 is sponsored by Mills Clinical Research.

What drugs are being tested in NCT03275701?

Interventions in NCT03275701: Triumeq.

What condition does NCT03275701 study?

NCT03275701 studies Infection, Human Immunodeficiency Virus.

Is NCT03275701 still recruiting?

NCT03275701 is currently status unknown. Last updated 5 September 2017.

Last reviewed 2017-09-05 · How we verify

NCT03275701: STRUCTR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase IV, Single-Arm, Open-Label Study Evaluating Bone Mineral Density in HIV-1-Infected Adults ≥50 Years Old Switching From EVG/COBI/FTC/TAF (Genvoya) or EVG/COBI/FTC/TDF (Stribild) to ABC/DTG/3TC (Triumeq)

Status unknown NA Last updated 5 September 2017

What this trial tests

NA trial testing Triumeq in Infection, Human Immunodeficiency Virus in 50 participants. Status unknown.

Timeline

1 July 2016

Primary endpoint
1 October 2019

1 November 2019

Quick facts

Lead sponsor	Mills Clinical Research
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 July 2016
Primary completion	1 October 2019
Estimated completion	1 November 2019
Sites	1 location across United States

Drugs / interventions tested

Triumeq — full drug profile →

Conditions studied

Infection, Human Immunodeficiency Virus — all drugs for Infection, Human Immunodeficiency Virus →

Sponsor

Mills Clinical Research

Who can join

50 and older, any sex, with Infection, Human Immunodeficiency Virus. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percent change from Baseline at Week 48 in total hip BMD (measured by DEXA)
Time frame: 48 Weeks
Percent change from Baseline at Week 48 in lumbar spine BMD (measured by DEXA)
Time frame: 48 Weeks

Sponsor's own description

Phase IV, Single-Arm, Open-Label Study Evaluating Bone Mineral Density in HIV-1-Infected Adults ≥50 Years Old Switching from EVG/COBI/FTC/TAF (Genvoya) or EVG/COBI/FTC/TDF (Stribild) to ABC/DTG/3TC (Triumeq)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Triumeq

Trials testing the same drug.

NCT02509195 — SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over · Phase 4 · completed

Other recruiting trials for Infection, Human Immunodeficiency Virus

Currently open trials in the same condition.

NCT02951052 — Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpiv · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03275701 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mills Clinical Research
Last refreshed: 5 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03275701.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing